Pediatric Protocol In Written Agreement Should Be Strictly Followed - FDA
NDA sponsors will be expected to precisely adhere to study protocols included in pediatric written agreements, FDA's revised guidance on pediatric exclusivity states.
You may also be interested in...
FDA's sample written request for antihypertensive agent pediatric information specifies what types of studies will produce "meaningful" data for pediatric labeling.
FDA may seek to disseminate data collected from pediatric studies by alternate methods if enough sponsors do not include the results in labeling, the agency's June 29 "Qualifying for Pediatric Exclusivity" guidance states.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011